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The theophylline-enoxacin interaction: II. 
Changes in the disposition of 
theophylline and its metabolites during 
intermittent administration of enoxacin 
Enoxacin, an investigational anti-infective agent of 
the fluoroquinolone class, gained considerable attention 
as a result of its ability to alter the disposition of the- 
ophylline. Wijnands et al.' reported that nausea and 
vomiting developed in 8 of 10 patients when enoxacin 
was added to their theophylline drug regimens. In a 
subsequent report, Wijnands et al.' reported that 
when enoxacin was administered orally at 800 to 1200 
mg / day, a 2.6-fold increase in mean plasma theoph- 
ylline concentrations occurred. Maesen et al.' reported 
symptoms suggestive of theophylline toxicity in 12 of 
From the Department of Drug Metabolism and Phannacokinetics, 
Sterling Research Group, Rensselaer, the Department of Internal 
Medicine, School of Medicine, the College of Pharmacy, Depart- 
ment of Pharmacology, and the Upjohn Center for Clinical Phar- 
macology, University of Michigan, and Parke Davis Pharmaceu- 
tical Research Division, Warner Lambert Company, Ann Arbor. 
Supported by Parke Davis Pharmaceutical Research Division, Warner 
Lambert Company. 
Received for publication Jan. 16, 1989; accepted May 29, 1989. 
Reprint requests: John Wagner, PhD, Upjohn Center for Clinical 
Pharmacology, UJ-3705/ 0504, University of Michigan Medical 
Center, Ann Arbor, MI 48109. 
13/1/14289 
420 
The pharmacokinetics of theophylline and its three major metabolites, 3-methylxanthine, 1-methylurate, 
and 1,3-dimethylurate, were studied during intermittent administration of enoxacin. The addition of 
enoxacin (400 mg, twice daily) to a theophylline dosing regimen (150 mg, twice daily) resulted in an 
immediate fall in plasma theophylline metabolite concentrations. Mean steady-state theophyffine 
concentration in plasma during the dosing interval increased from 3.17 to 8.23 jr.g/ml. The mean 12- 
hour recovery of total theophylline metabolite decreased from 76.3 to 38.6 mg. After the discontinuation 
of enoxacin, but not theophylline, the plasma theophylline metabolite levels immediately increased to near 
or above the concentrations observed before enoxacin coadministration. Concurrently, theophylline 
concentrations decreased to levels equivalent to those observed before enoxacin coadministration. In 
general, the changes in plasma theophylline concentrations observed after the addition or discontinuation 
of enoxacin were complete within 3 days. (CLIN PHARMACOL THER 1989;46:420-8.) 
Mark C. Rogge, PhD, William R. Solomon, MD, Allen J. Sedman, MD, PhD, 
Peter G. Welling, PhD, Jeffrey R. Koup, PharmD, and John G. Wagner, PhD 
Rensselaer, N.Y., and Ann Arbor, Mich. 
15 patients taking enoxacin and theophylline concur- 
rently. The enoxacin-theophylline interaction continues 
to generate interest as the character of this phenomenon 
unfolds in the literature.4'5 
In our previous report' the interaction of the- 
ophylline and enoxacin as a function of enoxacin 
dose was described. That article described enoxacin- 
induced changes in the disposition of theophylline and 
its primary metabolites, 3-methylxanthine (3-MX), 
1-methylurate (1-MU), and 1 ,3-dimethylurate (1 ,3- 
MU). It was shown that enoxacin administration 
reduced theophylline plasma clearance in a dose- 
dependent fashion. Dose-dependent changes in the for- 
mation of theophylline metabolites were also observed. 
This study was designed to determine the time course 
of changes in the disposition of theophylline and its 
metabolites during intermittent administration of en- 
oxacin. Sustained-release theophylline (as a precaution 
against excessively high theophylline levels) was ad- 
ministered twice daily to subjects for 13 days. During 
the course of theophylline administration, enoxacin was 
added to the regimen for 5 days. With this intermittent 
dosing regimen, nearsteady-state plasma theophylline 
and metabolite concentrations were achieved at three 
different times: before, during, and after enoxacin coad- 
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ministration. Extensive sampling of blood and urine 
was conducted. This article describes the shifts that 
were observed in plasma concentrations and in urinary 
excretion of theophylline and three metabolites through- 
out the course of the study. 
METHODS 
Study design. The study had an eight-subject se- 
quential design. Subjects were given 150 mg theoph- 
ylline (one half of a 300 mg Theo-Dur tablet) orally 
every 12 hours (8 Am and 8 Pm) for 12 days (288 hours). 
On day 5 (96 hours), each subject began taking 400 
mg enoxacin, as a single film-coated tablet, with each 
theophylline dose. Enoxacin continued to be adminis- 
tered through the morning dose of theophylline on day 
9 (192 hours), at which time enoxacin administration 
was discontinued. 
Blood samples were drawn into heparinized vacu- 
tainers from each subject at the following times (time 
zero corresponds to just before the first dose of the- 
ophylline): 0, 60, 72, 73, 74, 76, 78, 80, 82, 84, 96, 
108, 120, 132, 144, 156, 168, 180, 192, 193, 194, 
196, 198, 200, 202, 204, 216, 228, 240, 252, 264, 
276, 288, 289, 290, 292, 294, 296, 298, 300, 312, 
324, 336, 348, and 360 hours. Plasma was immediately 
separated from each sample, quick frozen, and stored 
at -20° C until assayed. Blood sampling was partic- 
ularly extensive on day 4, just before enoxacin admin- 
istration was begun, on day 9, after 4 complete days 
of enoxacin coadministration, and on day 13, 4 days 
after enoxacin administration had been stopped. Urine 
was collected during each of the following time inter- 
vals: 0 (control), 72 to 84, 84 to 96, 96 to 108, 108 to 
120, 120 to 132, 132 to 144, 144 to 156, 156 to 168, 
168 to 180, 180 to 192, 192 to 204, 204 to 216, 216 
to 228, 228 to 240, 240 to 252, 252 to 264, 264 to 
276, 276 to 288, 288 to 300, 300 to 312, 312 to 336, 
and 336 to 360 hours. Urine volumes from each col- 
lection period were measured and recorded. A 10 ml 
aliquot of each collection was immediately frozen and 
stored at - 20° C until assayed. All plasma and urine 
samples were assayed for parent drug and metabolites 
within 2 weeks. 
Subjects who participated in the study were healthy, 
nonsmoking male volunteers; each had signed an in- 
formed consent form before participation in the study. 
Their ages ranged from 22 to 47 years (mean, 28.0 
years); their weights ranged from 147 to 183 pounds 
(mean, 169 pounds). All subjects adhered to a strict 
xanthine-free diet beginning 3 days before the first the- 
ophylline dose and extending for 3 days after the last 
theophylline dose. 
Assay analysis. HPLC assays for the quantitation of 
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enoxacin, theophylline, and metabolites in plasma and 
urine were described in a previous publication.' Each 
assay allowed the estimation of each compound's con- 
centration over a broad range adequate for the conduct 
of this study. 
Assay sensitivity and reproducibility. The lowest 
concentration on the plasma standard curves was 0.2 
p.g/m1 for theophylline and 0.02 lig/ ml for each the- 
ophylline metabolite. The lowest concentration on the 
plasma standard curves was 0.50 lig/ ml for enoxacin 
and 0.25 Rg/m1 for the enoxacin oxometabolite. Cor- 
responding concentrations for urine were 1.0 lig/m1 for 
theophylline and each theophylline metabolite, 5.0 
ml for enoxacin, and 2.5 lig/ ml for the enoxacin 
oxometabolite. These concentrations were considered 
to be the assay sensitivities, and all concentrations mea- 
sured below these values were taken as zero. 
Pharmacokinetic analysis. The onset of the inter- 
action was measured as a function of rising plasma 
theophylline concentrations vs time. The plasma the- 
ophylline concentration vs time data were fitted to the 
empiric first-order function: 
= Coexp'-' ° + C5(1 - exp(' 0) (1) 
in which C, is the estimated plasma concentration at 
time t, Co is the initial plasma concentration (mean of 
84- and 96-hour minimum steady-state drug concentra- 
tion in plasma [CI] values for onset and 192- and 204- 
hour [Csees,] values for offset), Cs, is an estimated pa- 
rameter equal to the new steady-state plasma concen- 
tration being approached, and k is the first-order rate 
constant that describes the rate of approach to the new 
steady state. The concentration-time data pairs were 
fitted by unweighted nonlinear least-squares regression 
analysis on PCNONLIN.' 
An approximate time required for theophylline to 
reach 80% of steady-state plasma concentrations with 
multiple dosing was calculated as follows: 
Tee = (2.32) (0.693/k) (2) 
in which k is the rate constant defined in equation 1. 
First-order terminal elimination rate constants (Ice) 
were estimated by unweighted nonlinear least-squares 
regression of the log-linear plasma concentration-time 
data. The plasma elimination half-life (t2) was deter- 
mined by dividing ke into 0.693. The AUC from 0 hours 
through T (AUCV) was estimated with the trapezoidal 
rule. The total amount of theophylline metabolite re- 
covered in urine (as theophylline equivalents) during 
each collection interval was calculated with the follow- 
ing equation: 
Total metabolite = (1.09) (am(3-mx) + 
(0.990) (am(i-mu) + (0.919) (am(/,3-mu) (3) 
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Fig. 1. Mean plasma theophylline concentration-time profile. The time period shown (60 to 360 
hours) includes each of the three steady-state periods. Theophylline was administered as a Theo- 
Dur tablet, 150 mg, every 12 hours through 300 hours. Short-term rises in plasma theophylline 
concentrations (72 to 84, 192 to 204, and 288 to 300 hours) occurred during periods of frequent 
blood sampling after theophylline administration. 
in which MWTheo/MW3-mx = 1.09, MWTheo/MWI-MU = 
0.990, and MW MW Theo/ - I,3-MU = 0.919. 
Renal clearances (CLR) were estimated by division 
of the amount of compound recovered in urine during 
each 12-hour time period by the compound's respective 
plasma AUC during the same time period. 
Statistical analysis. All statistical analyses were con- 
ducted on an IBM 3090-400 mainframe computer (IBM 
Corp., Danbury, Conn.). The software system SAS 
(version 5.15) was used. General linear model proce- 
dures were used to conduct the ANOVAs; Scheffe's 
method of contrasting parameter values was followed. 
The Scheffe method (a = 0.05) was used in lieu of 
the Tukey and Bonferroni methods because testing of 
multiple contrasts was conducted. 
RESULTS 
Assay reproducibility. Least-squares regression anal- 
ysis was conducted on the plasma and urine assay val- 
idation data for theophylline and its three metabolites. 
For plasma calibration curve standards, mean coeffi- 
cients of variation ranged from 2.38% to 4.04% for 
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theophylline, 1.14% to 7.44% for 3-MX, 2.14% to 
3.98% for 1-MU, and 1.79% to 5.36% for 1,3-MU. 
For urine, mean coefficients of variation ranged from 
1.01% to 1.77% for theophylline, 1.74% to 7.25% for 
3-MX, 5.35% to 9.87% for 1-MU, and 2.75% to 9.32% 
for 1,3-MU. 
In the enoxacin and enoxacin oxometabolite plasma 
assay, the mean coefficients of variation from analysis 
of calibration curve data ranged from 2.10% to 4.04% 
and from 3.31% to 7.82%, respectively. In the enoxacin 
and enoxacin oxometabolite urine assay, the mean co- 
efficients of variation ranged from 3.05% to 7.59% and 
from 3.20% to 5.74%, respectively. 
Coefficients of variation estimated from the assay of 
quality control standards at the same time were of the 
same magnitude as those listed above. 
Theophylline and metabolites. Fig. 1 presents mean 
plasma theophylline concentrations versus time during 
the course of the study. Table I contains mean Css , C, and t,ax values of theophylline at steady state for 
each treatment phase. The initial mean theophylline 
steady-state parameters, C SmSo C and tmax, ob- 
Theophylline Ceases Enoxacin Begins 
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Table I. Steady-state pharmacokinetic parameters of theophylline before, during, and after 
enoxacin administration 
*C,, occurred just before administration of theophylline. 
tSignificantly higher than before and after values, which are not significantly different from one another (p < 0.05). 
Table II. Parameter values associated with apparent first-order increase and subsequent decreases in plasma 
theophylline concentrations* 
tamed during the 72- to 84-hour time period were 3.17 
p.g/ml, 4.79 p,g/ml, and 4.8 hours, respectively. Four 
days after commencement of enoxacin coadministration 
(192 to 204 hours into the study), the mean parameter 
values at the new theophylline steady state were 8.23 
p.g/ml, 9.99 lig / ml, and 3.8 hours, respectively. 
Theophylline C2n values were determined to be at 
steady state through ANOVA of the plasma concentra- 
tion data. Steady state was assumed when the concen- 
tration difference between two consecutive time points 
was not found to be significantly different. By this 
method of analysis, a new theophylline steady state was 
achieved within 48 hours of commencement of enoxacin 
administration and within 72 hours of discontinuance 
of enoxacin administration. 
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*The three periods in which the regressions were conducted were when enoxacin administration commenced, when enoxacin administration was discontinued, and 
when theophylline was discontinued. 
Theophylline CI values between the 72- to 84- 
hour and 192- to 204-hour time periods were signifi- 
cantly different. Similarly, there was a statistically sig- 
nificant difference between the respective Cs,1 values. 
There were no significant differences between the tmax 
values. 
The rise in plasma theophylline concentrations ap- 
peared to be described adequately by a first-order pro- 
cess (Fig. 1). Therefore CI values from the 84- to 
204-hour time interval were fitted to equation 1. Table 
II contains the relevant regression parameters. Coeffi- 
cients of determination (r2) ranged from 0.702 to 0.964 
for the individual data. The first-order onset rate con- 
stants ranged from 0.0150 to 0.0559 hr., with a mean 
of 0.0354 hr. The function intercept, or theoretic new 
Before During After 
Subject CL ( pg I ml) C ( mg! ml) t, (hr) ain ( gg I ml) C, ( gg I ml) (hr) a, (/v/ml) C. (agI ml) t, (hr) 
1 2.55 5.24 4.0 8.97 10.1 6.0 3.75 5.10 6.0 
2 1.91 3.56 4.0 6.48 8.12 8.0 3.25 4.09 2.0 
3 3.10 4.11 4.0 8.66 9.67 4.0 3.77 5.88 4.0 
4 2.32 3.07 8.0 7.05 8.43 2.0 3.01 4.55 4.0 
5 3.76 4.35 4.0 9.75 11.9 4.0 3.33 4.38 2.0 
6 5.20 8.23 4.0 8.74 10.8 0* 4.07 5.99 1.0 
7 4.35 6.00 6.0 8.74 10.7 2.0 3.58 4.69 6.0 
8 2.19 3.74 4.0 7.42 10.2 4.0 2.71 3.72 8.0 
Mean 3.17 4.79 4.8 8.231' 9.99t 3.8 3.43 4.80 4.1 







Subject k (hr-') r2 k (hr- ) r2 k (hr- ' ) r2 
1 0.043 0.878 0.015 0.933 0.076 0.992 
2 0.037 0.901 0.027 0.736 0.105 0.961 
3 0.033 0.861 0.033 0.955 0.077 0.975 
4 0.032 0.897 0.014 0.953 0.080 0.966 
5 0.015 0.964 0.014 0.901 0.070 0.993 
6 0.017 0.722 0.021 0.801 0.076 1.00 
7 0.056 0.702 0.025 0.964 0.070 0.990 
8 0.051 0.927 0.046 0.929 0.074 0.997 
Mean 0.035 0.024 0.079 
SD 0.015 0.011 0.011 
424 Rogge et al. 
B, Before enoxacin administration; D, during enoxacin administration; A, after enoxacin administration. 
*Significantly higher than before and after values, which are not significantly different from one another (p < 0.05). 
tSignificantly lower than before and after values, which are not significantly different from one another (p <0.05). 
No significant difference between before, during, and after values. 
steady-state plasma concentration, was 9.04 [IT/mi. 
The observed time to achieve a new steady-state plasma 
theophylline concentration was between 48 and 60 
hours. The harmonic mean (SD) of the theoretic time 
required to achieve 80% of the new steady-state con- 
centration was 45.4 (18.8) hours. Fig. 2 presents mean 
observed and predicted plasma theophylline concentra- 
tions versus time after commencement of enoxacin 
coadministration. 
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Mean 12-hour plasma theophylline AUC values were 
49.6 and 111 hr/ ml before and during enoxacin 
coadministration, respectively (Table III). The differ- 
ence between these values was statistically significant. 
The mean 12-hour AUC values before enoxacin coad- 
ministration were 0.836, 1.08, and 2.55 lig hr/ml for 
3-MX, 1-MU, and 1,3-MU, respectively. The mean 
12-hour AUC values during enoxacin coadministration 
were 0.044, 0.389, and 1.80 lig hr / ml for 3-MX, 
Subject 
Theophylline 3-MX 1-MU 1,3-MU 
B D A B D A B D A B D A 
1 53.8 114 55.6 1.19 0.085 2.03 0.405 0.426 0.930 1.47 0.349 2.55 
2 33.6 89.0 44.5 1.55 0 0.391 0.318 0.224 0.655 0.977 0.417 1.92 
3 44.9 113 59.2 0.170 0.175 3.03 0.811 0.586 1.14 2.46 3.52 3.11 
4 33.6 94.2 45.9 0.271 0 0.304 0.580 0.354 0.744 1.27 2.86 2.33 
5 48.8 133 46.0 1.09 0 0.172 1.89 0.689 2.13 4.22 2.21 3.61 
6 84.0 118 61.8 0.687 0 1.29 1.41 0.738 1.43 3.43 0.530 3.51 
7 60.1 118 49.1 0.813 0 0.848 1.60 0 1.50 2.98 2.29 2.08 
8 38.1 106 38.7 0.930 0.091 1.02 1.63 0.100 1.44 3.58 2.19 2.61 
Mean 49.6 111* 50.1 0.836 0.0441: 1.14 1.08 0.3891: 1.25 2.55 1.80* 2.72 
SD 16.8 14.1 7.99 0.461 0.066 0.977 0.621 0.271 0.483 1.20 1.21 0.634 
75 100 125 150 175 200 225 
Time (hr) 
Fig. 2. Mean observed plasma theophylline concentration profile during onset of interaction. Mean 
predicted plasma concentrations overlay the observed values. 
Table III. Plasma AUCs for theophylline and its major metabolites before (72 to 84 hours), during (192 to 
204 hours), and after (288 to 300 hours) enoxacin administration 
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Table IV. Steady-state plasma concentrations of the major metabolites of theophylline before, during, and 
after enoxacin administration 
1-MU, and 1,3-MU, respectively. The 12-hour AUC 
values for 3-MX and 1-MU were significantly lower 
during enoxacin coadministration than before enoxacin 
coadministration. 
Table IV contains mean steady-state CI values for 
each metabolite before, during, and after enoxacin 
coadministration. Mean steady-state Csms, values of 
3-MX, 1-MU, and 1,3-MU before enoxacin coadmin- 
istration were 0.057, 0.083, and 0.193 Rg/ml, respec- 
tively. During enoxacin coadministration, these con- 
centrations decreased to 0.005, 0.025, and 0.135 
respectively. Between these study periods, 
there were statistically significant differences in the 
B, Before enoxacin administration; D, during enoxacin administration; A, after enoxacin administration. 
*Significantly higher than before and during values, which are not significantly different from one another (p < 0.05). 
tSignificantly lower than before and after values, which are not significantly different from one another (p < 0.05). 
*No significant differences between before, during, and after values. 
Table V. The amounts of each theophylline metabolite excreted in the urine at steady state before enoxacin 
coadministration (72 to 84 hours) and during enoxacin coadministration (192 to 204 hours) 
*Significantly different from the corresponding amount during enoxacin coadministration (p < 0.05). 
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Cssn values for both 3-MX and 1-MU but not for 1,3- 
MU. In two subjects (Nos. 3 and 4) the plasma 1,3- 
MU concentration increased after commencement of 
enoxacin coadministration. 
Table V contains the mean amount of each theoph- 
ylline metabolite recovered in the urine during the 72- 
to 84-hour and 192- to 204-hour time periods. The mean 
amounts of 3-MX, 1-MU, and 1,3-MU recovered be- 
fore and during enoxacin coadministration were 10.5 
and 4.99 mg, 21.5 and 8.25 mg, and 47.5 and 
27.3 mg, respectively. The mean (SD) ratio of total 
metabolite recovered during enoxacin coadministration 
(38.6 mg) to total metabolite recovered before enoxacin 
Subject 
C plasma concentration ( jug I ml) 
3-MX 1-MU 1, 3-MU 
B D A B D A B D A 
1 0.085 0.011 0.232 0.045 0.024 0.086 0.133 0.018 0.021 
2 0.045 0.010 0.053 0.019 0.037 0.057 0.081 0.030 0.152 
3 0.053 0.019 0.166 0.090 0.038 0.068 0.186 0.273 0.187 
4 0.043 0 0.197 0.045 0.042 0.064 0.084 0.247 0.160 
5 0.054 0 0.012 0.150 0.023 0.151 0.378 0.158 0.247 
6 0.052 0 0.125 0.092 0.039 0.139 0.228 0.046 0.272 
7 0.058 0 0.066 0.099 0 0.106 0.232 0.132 0.163 
8 0.068 0 0.099 0.123 0 0.111 0.221 0.176 0.190 
Mean 0.057 0.005 0.119* 0.083 0.025t 0.098 0.193 0.1351 0.197 
SD 0.013 0.007 0.076 0.044 0.017 0.035 0.097 0.097 0.043 
Subject 
Before During 
Ratio of total 
metabolites 
during/before 3-MX 1-MU 1,3-MU 
Total metabolite 
theophylline 




I 3.53 7.74 34.2 42.9 0.929 4.16 5.68 10.3 0.240 
2 7.09 22.0 24.1 51.6 1.41 3.43 24.5 27.4 0.531 
3 2.98 4.61 14.1 20.7 1.09 1.46 14.9 16.3 0.787 
4 4.98 8.40 20.8 32.9 2.14 1.63 22.1 24.2 0.736 
5 14.9 34.8 52.1 98.5 14.6 10.9 29.4 53.6 0.544 
6 17.8 26.5 78.0 117 7.07 9.74 7.70 24.4 0.209 
7 13.5 23.5 61.5 94.4 6.48 16.1 56.8 75.1 0.796 
8 19.1 44.6 95.2 152 6.17 18.6 57.0 77.5 0.510 
Mean 10.5* 21.5* 475* 76.3* 4.99 8.25 27.3 38.6 
SD 6.58 14.1 29.2 46.1 4.67 6.63 20.0 26.5 
- 
- 
175 200 225 250 2+5 300 
Time (hr) 
Fig. 3. Mean observed plasma theophylline concentration profile during offset of interaction. Mean 
predicted plasma concentrations overlay the observed values. 
coadministration (76.3 mg) was 0.544 (0.228), with a 
range of 0.209 to 0.796. 
After enoxacin was discontinued, plasma theophyl- 
line concentrations decreased, with a mean first-order 
rate constant of 0.0244 hr' (Table II). The coefficients 
of determination for the eight regressions ranged from 
0.736 to 0.964. The harmonic mean (SD) of the the- 
oretic time required to achieve 80% of steady state was 
65.9 (32.5) hours. ANOVA of CI values indicated that 
steady state had been achieved between 60 and 72 
hours. Fig. 3 presents mean observed and predicted 
plasma theophylline concentrations versus time. During 
the 288- to 300-hour sampling period, mean steady- 
state theophylline Cs,1, C, and t.,,,a,, values were 
3.43 kg / ml, 4.78 p,g /ml, and 4.1 hours, respectively. 
The steady-state theophylline Csms, and Csmsa values 
after enoxacin had been discontinued were each sig- 
nificantly less than during enoxacin coadministration. 
There were no statistically significant differences in 
theophylline Csms,, C,sms. or t,a values between the 
periods before enoxacin coadministration and after en- 
oxacin coadministration. 
Table II also contains the regression parameters of 
the fall in plasma theophylline concentrations after the- 
ophylline was discontinued. The mean Ica was estimated 
to be 0.079 and the coefficients of determination of the 
regressions ranged from 0.961 to 1.00. The harmonic 
theophylline elimination t2 was 8.83 hours. 
Mean steady-state Csms values for 3-MX, 1-MU, and 
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1,3-MU after discontinuation of enoxacin were 0.119, 
0.0978, and 0.197 kg /ml, respectively. Steady-state 
CI plasma concentrations of 3-MX after discontin- 
uation of enoxacin were significantly greater than 
steady-state 3-MX C values both before and during 
enoxacin coadministration. Plasma 1-MU concentra- 
tions were significantly lower during enoxacin coad- 
ministration than after enoxacin coadministration. 
Plasma 1,3-MU concentrations during enoxacin coad- 
ministration were not significantly different from those 
after enoxacin was discontinued. 
After enoxacin was discontinued, the mean steady- 
state 12-hour plasma AUC values for 3-MX, 1-MU, 
and 1,3-MU were 1.14, 1.25, and 2.72 1.1.g hr/ ml, 
respectively. The plasma AUC values for 3-MX and 
1-MU were significantly greater than their respec- 
tive values during enoxacin coadministration but not 
different from those determined before enoxacin coad- 
ministration. 
Enoxacin and oxometabolite. Fig. 4 presents mean 
plasma enoxacin concentrations versus time during the 
course of the study. After approximately 36 hours of 
twice-daily oral administration, plasma enoxacin con- 
centrations were at steady state, yielding a mean C 
value of 0.88 kg /ml. At the 216-hour sampling time, 
12 hours after the last enoxacin dose, plasma enoxacin 
concentrations were below the minimum quantifiable 
level in all subjects. 
In general, plasma concentrations of the enoxacin 















oxometabolite were below the minimum detectable 
level. Only between 180 and 204 hours were mean 
plasma concentrations greater than zero. The mean (SD) 
12-hour plasma enoxacin oxometabolite concentrations 
were 0.0313 (0.0884), 0.0419 (0.118), and 0.0374 
(0.106) g/m1 at 180, 192, and 204 hours, respec- 
tively. The low plasma concentrations of enoxa- 
cin oxometabolite precluded further pharrnacokinetic 
analysis. 
No significant differences in theophylline or theoph- 
ylline metabolite CLR were detected among the three 
steady-state theophylline phases. 
DISCUSSION 
This study was designed to characterize plasma con- 
centrations of theophylline and its metabolites during 
intermittent enoxacin administration. The results indi- 
cate that plasma concentration profiles of theophylline 
and its metabolites changed substantially when enox- 
acin was added to the drug regimen. 
In enoxacin-naive subjects, plasma theophylline con- 
centrations were at steady-state levels by 60 hours into 
the theophylline dosing schedule (Fig. 1). After en- 
oxacin coadministration was begun, an immediate rise 
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Fig. 4. Mean plasma enoxacin concentration-time profile. Enoxacin administration began at 96 
hours and was discontinued at 204 hours. Enoxacin tablets (400 mg) were administered with each 
theophylline dose. Blood samples were collected frequently between 192 hours and 204 hours, 
resulting in the apparent rise in plasma enoxacin concentrations. 
in plasma theophylline concentrations occurred. The 
mean estimated new steady-state plasma theophylline 
concentration, 9.04 lig /ml, was very close to the ob- 
served mean value of 8.53 1.i.g / ml. 
Assuming that the rise in plasma theophylline con- 
centrations occurred by an apparent first-order process, 
a new steady-state plasma concentration would have 
been reached within approximately 45 hours after com- 
mencement of enoxacin coadministration. This is sim- 
ilar to the observed time of approximately 48 hours. 
When enoxacin was added to the theophylline regi- 
men, a dramatic fall in plasma theophylline metabolite 
concentrations was observed. The mean steady-state 
3-MX CS,Sin fell from 0.0573 Rg/m1 to 0.00503 
Rg/ml, and the mean steady-state 1-MU CI fell from 
0.0829 lig / ml to 0.0252 lig /ml. 
The mean steady-state 1,3-MU CI, which appeared 
to be least affected by enoxacin coadministration in this 
study, fell from 0.193 lig/ ml to 0.135 t.t.g /ml. How- 
ever, in two subjects, plasma concentrations of 1,3-MU 
rose when enoxacin coadministration was begun. It is 
plausible that, in some subjects, the 1,3-MU pathway 
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Like the steady-state Csms, values for theophylline 
and each of its metabolites, the steady-state 12-hour 
AUC values shifted with enoxacin coadministration. 
The mean theophylline AUC more than doubled from 
49.6 1.1.g hr/ ml to 111 F.As hr/ ml; the increase was 
statistically significant. Conversely, AUC values for 
each theophylline metabolite fell; the 3-MX and 1-MU 
values fell significantly. 
The fall in plasma theophylline metabolite concen- 
trations coincided with a substantial fall in urinary re- 
covery of theophylline metabolites. Mean ratios of 
3-MX, 1-MU, and 1,3-MU recovered in urine ("dur- 
ing/before" enoxacin coadministration) at the steady- 
state time periods were 0.475, 0.384, and 0.575, re- 
spectively. Individual recovery values translated into a 
mean total theophylline metabolite ratio of 0.544. 
Hence the overall formation of theophylline major me- 
tabolites was suppressed by approximately 50% when 
twice-daily 400 mg doses of enoxacin were adminis- 
tered with 150 mg theophylline. 
When enoxacin administration was discontinued, 
plasma theophylline concentrations immediately began 
to fall to new steady-state levels. Plasma theophylline 
concentrations approached new steady-state levels 
within 3 days after discontinuation of enoxacin admin- 
istration. The predicted time to reach 80% of the new 
steady-state concentration (65.9 hours) agrees reason- 
ably well with the fall in observed plasma theophylline 
concentrations. The new steady-state concentrations 
were statistically indistinguishable from the steady-state 
concentrations before enoxacin administration. 
Theophylline metabolite concentrations responded 
immediately to the discontinuation of enoxacin admin- 
istration. Plasma concentrations of each metabolite be- 
gan to rise within 12 hours after the last enoxacin dose. 
After enoxacin administration was discontinued and 
CLIN PHARMACOL THER 
OCTOBER 1989 
plasma theophylline concentrations had reached a 
new steady state, 1-MU and 1,3-MU Csms, values 
were similar to values obtained before enoxacin ad- 
ministration. 
Our previous study' indicated that the degree of 
suppression of theophylline metabolism was dependent 
on the dose of enoxacin given. The present study 
showed that the time course for both the onset and the 
offset of the interaction is rapid. New steady-state the- 
ophylline and metabolite plasma concentrations are 
achieved within approximately 3 days of starting and 
stopping enoxacin dosage. Thus any untoward increase 
in plasma theophylline concentrations during enoxacin 
administration is readily manageable by reducing the 
theophylline dosage. 
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